Effect of remdesivir on mortality rate and clinical status of COVID-19 patients: a systematic review with meta-analysis
Carmine Sellitto, Graziamaria Corbi, Nicola Bertini, Tiziana Ascione, Maria Costantino, Giuliana Scarpati, Ornella Piazza, Amelia Filippelli, Valeria Conti, Pasquale Pagliano
Abstract
Remdesivir (RDV) is a broad-spectrum antiviral drug, now approved by Regulatory Agencies for COVID-19 treatment. RDV is associated with improvements in clinical outcomes, but no conclusive studies have shown an effect in reducing mortality. This study aimed to carry out a systematic review with meta-analysis to investigate whether RDV can significantly modify the outcome of COVID-19 patients evaluating its effects on mortality, length of stay, time to clinical improvement and need for oxygen supplementation. No significant improvement in terms of survival in patients treated with standard therapy (ST)+RDV as compared to ST alone (P = 0.24) was found. The duration of oxygen support was significantly lower in patients treated with ST + RDV compared with ST alone (P = 0.03). Further investigations should be planned to assess the real impact of RDV in the management of COVID-19 patients.